| Ethanol exposure during pregnancy persistently attenuates cranially directed blood flow in the developing fetus: evidence from ultrasound imaging in a murine second trimester equivalent model. | |
| | |
MedLine Citation:
|
PMID: 22141380 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Ethanol (EtOH) consumption during pregnancy can lead to fetal growth retardation, mental retardation, and neurodevelopmental delay. The fetal brain initiates neurogenesis and vasculogenesis during the second trimester, and depends on maternal-fetal circulation for nutrition and growth signals. We used high-resolution in vivo ultrasound imaging to test the hypothesis that EtOH interferes with fetal brain-directed blood flow during this critical developmental period. METHODS: Pregnant mice were lightly anesthetized on gestational day 12 with an isoflurane/oxygen mixture. We assessed the effect of single and repeated binge-like maternal EtOH exposures at 3 g/kg, administered by intragastric gavage or intraperitoneal injection, on maternal circulation and fetal umbilical, aortic, internal carotid, and middle cerebral arterial circulation. RESULTS: Binge maternal EtOH exposure, regardless of exposure route, significantly reduced fetal arterial blood acceleration and velocity time integral (VTI), from umbilical to cerebral arteries, without a change in fetal heart rate and resistivity indices. Importantly a single maternal binge EtOH exposure induced persistent suppression of fetal arterial VTI for at least 24 hours. Repeated binge episodes resulted in a continuing and persistent suppression of fetal VTI. Qualitative assessments showed that maternal EtOH exposure induced oscillatory, nondirectional blood flow in fetal cerebral arteries. Maternal cardiac and other physiological parameters remained unaltered. CONCLUSIONS: These data show that binge-type maternal EtOH exposure results in rapid and persistent loss of blood flow from the umbilical artery to the fetal brain, potentially compromising nutrition and the maternal/fetal endocrine environment during a critical period for neuron formation and angiogenesis in the maturing brain. |
| | |
Authors:
|
Shameena Bake; Joseph D Tingling; Rajesh C Miranda |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2011-12-05 |
Journal Detail:
|
Title: Alcoholism, clinical and experimental research Volume: 36 ISSN: 1530-0277 ISO Abbreviation: Alcohol. Clin. Exp. Res. Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-05-02 Completed Date: 2012-09-10 Revised Date: 2013-05-22 |
Medline Journal Info:
|
Nlm Unique ID: 7707242 Medline TA: Alcohol Clin Exp Res Country: England |
Other Details:
|
Languages: eng Pagination: 748-58 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 by the Research Society on Alcoholism. |
Affiliation:
|
Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M Health Science Center, Bryan, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adaptation, Physiological Alcohol Drinking / adverse effects Animals Central Nervous System Depressants / administration & dosage, adverse effects*, blood Cerebrovascular Circulation / drug effects* Ethanol / administration & dosage, adverse effects*, blood Female Fetal Alcohol Syndrome / etiology* Fetus / blood supply, drug effects* Head / blood supply Hemodynamics / drug effects Injections, Intraperitoneal Maternal Exposure / adverse effects Mice Pregnancy Pregnancy Trimester, Second Respiration / drug effects Ultrasonography, Prenatal |
| Grant Support | |
ID/Acronym/Agency:
|
R01 AA013440-06A1S1/AA/NIAAA NIH HHS; R01 AA013440-09/AA/NIAAA NIH HHS; R01 AA013440-10/AA/NIAAA NIH HHS; R01AA013440/AA/NIAAA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Central Nervous System Depressants; 64-17-5/Ethanol |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surgical nurses' perceptions of ethical dilemmas, moral distress and quality of care.
Next Document: Epigenetic-based therapies in cancer: progress to date.